A Placebo-controlled, Randomized, Observer-blinded, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Booster Vaccination of A SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AS03A (Primary) ; GBP 510 (Primary) ; Ad26.COV2 S; AZD 1222; Elasomeran; Tozinameran
Indications COVID 2019 infections
Focus Pharmacodynamics

Most Recent Events

12 Feb 2023 Planned number of patients changed from 550 to 770.
12 Feb 2023 Planned End Date changed from 1 May 2023 to 1 Nov 2023.
12 Feb 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight